Translate this page into:
Letter to the Editor
doi:
10.4103/sajc.sajc_157_19
An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast–ovarian cancer syndrome
1
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra
*Corresponding author: Dr. Vanita Noronha. vanita.noronha@gmail.com
MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Disclaimer:
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
References
- Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366:1382-92.
- Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12:852-61.
- O'Sullivan CC, Moon DH, Kohn EC, Lee JM. Beyond breast and ovarian cancers: PARP inhibitors for BRCA mutation-associated and BRCA-like solid tumors. Front Oncol 2014;4:42.
- Alexandrov LB, Stratton MR. Mutational signatures: The patterns of somatic mutations hidden in cancer genomes. Curr Opin Genet Dev 2014;24:52-60.
- Wainberg ZA, Rafii S, Ramanathan RK, Mina LA, Byers LA, Goldman RC, et al. Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients [abstract]. J Clin Oncol. 2014;32(5s). Abstract 7522.
- Owonikoko TK, Dahlberg SE, Sica GL, Wagner LI, Wade JL 3rd, Srkalovic G, et al. Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 Study. J Clin Oncol 2019;37:222-9.
- Molife LR, Roxburgh P, Wilson RH, Gupta A, Middleton MR, Michie TR, et al. A phase I study of oral rucaparib in combination with carboplatin.10.1200/jco.2013.31.15_suppl.2586 Journal of Clinical Oncology 2013;31:2586.
- Rajan A, Carter CA, Kelly RJ, Gutierrez M, Kummar S, Szabo E, et al. Aphase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res 2012;18:2344-51.
- Appleman LJ, Beumer JH, Jiang Y, Puhalla S, Lin Y, Ramalingam TK, et al. A phase I study of veliparib (ABT- 888) in combination with carboplatin and paclitaxel in advanced solid malignancies. 10.1200/jco.2012.30.15_suppl.3049 Journal of Clinical Oncology 2012;30:3049.
- A Randomised Phase II Trial of Olaparib Maintenance Versus Placebo Monotherapy in Patients with Chemosensitive Advanced Non-Small Cell Lung Cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01788332. [Last accesed on 2019 Apr 24].